Unknown

Dataset Information

0

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.

ABSTRACT:

SUBMITTER: Leske IB 

PROVIDER: S-EPMC11347367 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.

Leske Inga B IB   Hantschel Oliver O  

Leukemia 20240615 9

Similar Datasets

Unknown Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
| S-EPMC7566958 | biostudies-literature
Unknown Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
| S-EPMC11518997 | biostudies-literature
Unknown Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
| S-EPMC10133857 | biostudies-literature
Unknown Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
| S-EPMC6893878 | biostudies-literature
Unknown Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
| S-EPMC11771825 | biostudies-literature
Unknown Exploring the Allosteric Pathways of Asciminib in the Dual Inhibition of BCR-ABL1.
| S-EPMC12467782 | biostudies-literature
Unknown Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient.
| S-EPMC11971149 | biostudies-literature
Unknown Allosteric enhancement of the BCR-Abl1 kinase inhibition activity of nilotinib by cobinding of asciminib.
| S-EPMC9386466 | biostudies-literature
Unknown Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
| S-EPMC11347358 | biostudies-literature
Unknown A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210<sup>BCR-ABL1</sup> and P195<sup>BCR-ABL1</sup> isoforms.
| S-EPMC6278977 | biostudies-literature